117 related articles for article (PubMed ID: 16897428)
1. Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer.
Kulkarni G; Turbin DA; Amiri A; Jeganathan S; Andrade-Navarro MA; Wu TD; Huntsman DG; Lee JM
Breast Cancer Res Treat; 2007 Mar; 102(1):31-41. PubMed ID: 16897428
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
[TBL] [Abstract][Full Text] [Related]
3. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
5. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer.
Anand N; Murthy S; Amann G; Wernick M; Porter LA; Cukier IH; Collins C; Gray JW; Diebold J; Demetrick DJ; Lee JM
Nat Genet; 2002 Jul; 31(3):301-5. PubMed ID: 12053177
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.
Mita K; Zhang Z; Ando Y; Toyama T; Hamaguchi M; Kobayashi S; Hayashi S; Fujii Y; Iwase H; Yamashita H
Jpn J Clin Oncol; 2007 Aug; 37(8):575-82. PubMed ID: 17675285
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
8. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration.
Amiri A; Noei F; Jeganathan S; Kulkarni G; Pinke DE; Lee JM
Oncogene; 2007 May; 26(21):3027-40. PubMed ID: 17130842
[TBL] [Abstract][Full Text] [Related]
9. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
11. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ
Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153
[TBL] [Abstract][Full Text] [Related]
12. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
13. eEF1A2 as a putative oncogene.
Lee MH; Surh YJ
Ann N Y Acad Sci; 2009 Aug; 1171():87-93. PubMed ID: 19723040
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
[TBL] [Abstract][Full Text] [Related]
15. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
17. High HSP90 expression is associated with decreased survival in breast cancer.
Pick E; Kluger Y; Giltnane JM; Moeder C; Camp RL; Rimm DL; Kluger HM
Cancer Res; 2007 Apr; 67(7):2932-7. PubMed ID: 17409397
[TBL] [Abstract][Full Text] [Related]
18. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
